
TRAIN Newsletter September 2021

Statement at Multi-Stakeholder meeting in support of the UN High-Level Meeting on Pandemic Prevention, Preparedness and Response

Food and Drug Administration (FDA) - Patient Perspectives on Gene Therapy Products

TRAIN Newsletter — September 2023

Comment Letter: Prescription Drug User Fee Act VII (PDUFA)

TRAIN Newsletter — June 2022

National Institutes of Health (NIH) Director Nomination

Milken Institute statement on ARPA-H inclusion in FY2022 spending bill

End of Year Legislative Package – Health Provisions

Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870
